Real-world data on neoadjuvant chemotherapy with dual-anti HER2 therapy in HER2 positive breast cancer

BMC Cancer

Table 3 Multivariate logistic regression models predicting total pathological complete response

Variables	Coefficient	OR (95% CI)	P-value
Age	-0.020	0.980 (0.957,1.004)	0.108
Tumor stage
cT1-2		Reference
cT3-4	-0.362	0.697 (0.422,1.150)	0.158
Lymph node status
Negative		Reference
Positive	-0.455	0.634 (0.330,1.221)	0.173
ER status
Negative		Reference
Positive	-0.829	0.437 (0.241,0.789)	0.006
PR status
Negative		Reference
Positive	-1.077	0.341 (0.160,0.724)	0.005
Ki-67 index
< 30%		Reference
≥ 30%	1.225	3.404 (1.357,8.538)	0.009
HER2 status
2 +		Reference
3 +	1.326	3.765 (1.776,7.985)	< 0.001
Chemotherapy regimens
THP*4		Reference
TCbHP*6	1.005	2.733 (1.562,4.782)	< 0.001
AC4-THP4	1.138	3.121 (1.257,7.748)	0.014

Logistic regression prediction model: \(\pi (Y=1)=\frac{1}{1+\mathit{exp}(-Score)}\)
\(\begin{array}{l}score=-0.829\left(\text{ER}=\text{Positive}\right)-1.077\left(\text{PR}=\text{Positive}\right)+1.225(\text{Ki}-67\\\geq30\%)+1.326\left(\text{HER}2=3+\right)+1.005(\mathrm{chemotherapy}\;\mathrm{regimen}=\text{TCbHP}\ast6)\\+1.138(\mathrm{chemotherapy}\;\mathrm{regimen}=\text{AC}\ast4-\text{THP}\ast4)\end{array}\)

ISSN: 1471-2407